Newron Initiates U.S. Phase II Trial in Patients with Schizophrenia

PRESS RELEASE: Newron Pharmaceuticals S.p.A. ("Newron"), a research and development company focused on novel CNS and pain therapies, announced today the initiation of a U.S. Phase II study with its novel sodium channel blocker, NW-3509, in patients...